+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hospital Infection Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • January 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4987000
UP TO OFF until Dec 31st 2023

The global hospital infection therapeutics market is expected to witness CAGR of 4.6% over the forecast period. The primary driving factors for the growth of the market include increasing incidence of hospital acquired infectious diseases coupled with the increasing geriatric population who are susceptible to diseases. In addition, the high number of pipeline drugs specifically developing for the hospital acquired infections and an increase in R&D investments expected to boost the market growth over the forecast period. Moreover, insufficient hospital infrastructure and low awareness on the usage of infusion systems in underdeveloped countries around the world projected to fuel the usage of hospital infection therapeutics market. However, continuous efforts by the government and healthcare providers in minimizing the hospital infections coupled with stringent regulations in the development of therapeutics is expected to hamper the market growth over the forecast period.

Key Market Trends

Antibacterial Segment is expected to Grow at Significant Rate

  • Antibacterial drugs used for hospital infections are expected to grow at significant rates owing to increasing initiatives on bacterial resistance, growing incidence of bacterial hospital infections.
  • According to the World Health Organization (WHO), with 100 hospitalised patients at any given time, 10 in developed and 7 in developing countries acquire minimum one healthcare-associated infection.
  • Urinary tract infections are expected to have a notable share in indications segment and is expected to grow at significant rates. The growth is attributed to the increasing number of patients with urinary tract infections and ongoing research and development on urinary tract infection treatment.
  • Moreover, the rise in the older population and prevalence of hospital acquired infection fuelling the overall market growth over the forecast period.

North America Expected to have Significant Market Share

North America region is anticipated to have significant market share owing to the growing number of multidrug-resistant pathogens coupled with the presence of key market players focusing on innovating therapeutic options. According to the Center for Disease Control and Prevention (CDC), in American hospitals alone, about 1.7 million people are affected by the hospital acquired infections each year. Asia Pacific hospital infection therapeutics market is projected to have considerable growth rate owing to the presence of developing and underdeveloped healthcare centers having low awareness regarding the hospital infection control systems and growing incidence of hospital acquired infections. Moreover, companies’ interest in expanding to the unaddressed markets in the Asia Pacific region is anticipated to fuel the regional growth.

Competitive Landscape

Global hospital infection therapeutics market is moderately fragmented and competitive. Market players are focusing on product innovations, new product launches and regional expansions to increase their market share. The key market players operating in hospital infection therapeutics market include Merck & Co., Inc., Allergan, AstraZeneca plc, Johnson & Johnson and F. Hoffmann-La Roche AG among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Demand for Non-Invasive Dermatology Techniques and Ageing Population
4.2.2 Increasing R&D Investments for New Hyaluronic Acid Based Dermal Fillers
4.3 Market Restraints
4.3.1 Lack of Skilled Professionals
4.3.2 High Cost of Dermal Filling Procedures
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Drug Type
5.1.1 Antibacterial Drugs
5.1.2 Anti-fungal Drugs
5.1.3 Antiviral Drugs
5.1.4 Others
5.2 By Indication
5.2.1 Blood Stream Infections
5.2.2 Urinary Tract Infections
5.2.3 Surgical Site Infections
5.2.4 Pneumonia
5.2.5 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Allergan plc
6.1.2 Merck & Co., Inc.
6.1.3 Johnson & Johnson
6.1.4 AstraZeneca
6.1.5 F. Hoffmann-La Roche AG
6.1.6 Bayer AG
6.1.7 GlaxoSmithKline plc
6.1.8 Cubist Pharmaceuticals, Inc.
6.1.9 Sanofi S.A.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergan plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • AstraZeneca
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • GlaxoSmithKline plc
  • Cubist Pharmaceuticals, Inc.
  • Sanofi S.A.